Isoket (Isosorbide Dinitrate)

After absorption, isosorbide dinitrate is converted to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing veins and arteries to relax, lowering preload and afterload, and ultimately decreasing myocardial oxygen consumption.

The specific dose and dosing schedule of Isoket are determined by the prescribing clinician based on the individual’s condition, response, and tolerance. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for isosorbide dinitrate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Isoket, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Isoket belongs to the nitrate class, offering rapid vasodilation and reduction of myocardial oxygen demand. Compared with beta‑blockers or calcium‑channel blockers, nitrates provide a distinct mechanism and are often used when those agents are insufficient or contraindicated.

Isoket should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures.

Isoket is administered via the oromucosal route. The tablet or film is placed in the mouth and allowed to dissolve, ensuring rapid absorption through the mucous membranes. Patients should follow the specific administration instructions provided by their healthcare provider.

The most serious risks include severe hypotension, syncope, and rare allergic reactions such as rash or swelling. Patients should seek immediate medical attention if they experience fainting, a sudden drop in blood pressure, or signs of an allergic response.

Isoket should be avoided in patients who are concurrently using other nitrates, phosphodiesterase‑5 inhibitors, or have known hypersensitivity to isosorbide dinitrate. Individuals with severe anemia, recent myocardial infarction, or uncontrolled hypotension should also be evaluated carefully before use.